Abdominal wall perforation in a patient with recurrent epithelial ovarian cancer after bevacizumab treatment
Received Date : 10 Mar 2016
Accepted Date : 28 Jul 2016
Doi: - Article's Language: EN
Journal of Oncological Science 2 (2016) 95-96
This is an open access article under the CC BY-NC-ND license
Bowel perforation is a rare but well-described complication of bevacizumab, a VEGF monoclonal antibody. However, bevacizumab associated abdominal wall perforation is a more serious complication. In here, a patient with recurrent epithelial ovarian cancer developing both bowel and abdominal wall perforation after bevacizumab treatment is reported with review of the literature to point out the clinical significance of this rare complication. To our knowledge, this is the first case with bevacizumab associated abdominal wall perforation.